Nika Pharmaceuticals, Inc.
NIKA
$0.75
$0.3797.21%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 196.80% | -4.76% | -18.22% | -71.96% | 71.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 196.80% | -4.76% | -18.22% | -71.96% | 71.23% |
| Operating Income | -196.80% | 4.76% | 18.22% | 71.96% | -71.23% |
| Income Before Tax | -196.80% | 4.76% | 18.22% | 71.96% | -71.23% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -196.80% | 4.76% | 18.22% | 71.96% | -71.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -196.80% | 4.76% | 18.22% | 71.96% | -71.23% |
| EBIT | -196.80% | 4.76% | 18.22% | 71.96% | -71.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -- | 100.00% | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | 100.00% | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 3.89% | 2.09% | 0.77% | 17.15% | 17.70% |
| Average Diluted Shares Outstanding | 3.89% | 2.09% | 0.77% | 17.15% | 17.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |